IXICO plc Issue of Equity (8391K)
07 Enero 2021 - 01:00AM
UK Regulatory
TIDMIXI
RNS Number : 8391K
IXICO plc
07 January 2021
IXICO plc
("IXICO" or the "Company")
Issue of Equity
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , announces that it has made an
application to the London Stock Exchange for the admission to
trading on AIM of 45,176 new ordinary shares of 1p each ("New
Shares") to satisfy the exercise of options.
The New Shares are expected to be admitted to trading on AIM on
12 January 2021.
Total voting rights
Application has been made for admission to trading on AIM of
45,176 New Shares. Admission of the New Shares on AIM is expected
to become effective at 8.00 a.m. on 12 January 2021, following
which there will be in total 47,136,468 ordinary shares in the
capital of the Company in issue, each carrying equal voting
rights.
This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in,
IXICO under the FCA's Disclosure and Transparency Rules.
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFLFVDLEIRIIL
(END) Dow Jones Newswires
January 07, 2021 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024